Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.